Research programme: antipsychotics - Cenomed BioSciences

Drug Profile

Research programme: antipsychotics - Cenomed BioSciences

Alternative Names: CM-2,303; CM-2,393

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cenomed BioSciences LLC
  • Developer Cenomed BioSciences
  • Class
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists; Dopamine D2 receptor modulators; Dopamine D3 receptor agonists; Dopamine D4 receptor antagonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in USA (PO)
  • 30 Jun 2010 Celgene Corporation to acquire Abraxis BioScience
  • 19 Nov 2008 Preclinical pharmacodynamics data presented at the 38th Annual Meeting of the Society for Neuroscience (SfN-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top